Status: Invested (closing date: December 2016)
Industry: Pharmaceutical CDMO
Type of investment: Development Capital
Equity stake: 96.76%
Turnover: Eur 40.0 mln
Established in 1998 through the spin-off of Novartis’ plant in Milan, Mipharm is an Italian leading Pharmaceutical Contract Development & Manufacturing Organization (“CDMO”). The Company is engaged in the manufacturing and packaging of a wide range of Finished Dosage Formulations (“FDFs”), with a client base of Big Pharma and global generic companies. In addition, Mipharm provides R&D services based on customer specific requirements and/or in house R&D.